Chusny Syndrome

LoGerfo FW, Horton ES, Veves A. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes 1999; 48:1856-1862.

38. Balletshofer BM, Rittig K, Enderle MD, Volk A, Maerker E, Jacob S, Matthaei S, Rett K, Haring HU. Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 2000; 101:1780-1784.

39. Festa A, D'Agostino Jr R, Howard G, Mykkanen, L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome. Circulation 2000; 102:42-47.

40. Pickup JC, Mattock MB, Chusny GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin 6 with metabolic syndrome X. Diabetologia 1997; 40:1286-1292.

41. Frohlich M, Imhof A, Berg G, Hutchinson WL, Pepys MB, Boeing H, Muche R, Brenner H, Koenig W. Association between C-reactive protein and features of the metabolic syndrome. Diabetes Care 2000; 23:1835-1839.

42. Mallinow MR, Bostom AG, Krauss RM. Homocyst(e)ine, diet, and cardiovascular diseases. A statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 1999; 99:178-182.

43. The Expert Committee on the Diagnosis and Classification of Diabetes. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2001; 24(1):S5-S20.

44. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RL, Ho-meostatis model assessment: insulin resistance and ß cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419.

45. Haffner SM, Miettinen H, Stern MP. The homeostasis model in the San Antonio Heart Study. Diabetes Care 1997; 20(7):1087-1092.

46. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237:E214-223.

47. Bergman RN, Phillips LS, Cobelli C. Physiologic evaluation of factors controlling glucose tolerance in men: measurement of insulin sensitivity and ß cell glucose sensitivity from the response to intravenous glucose. J Clin Invest 1981; 68:1456-1467.

48. Bergman RN, Prager R, Volund A, Olefsky JM. Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. J Clin Invest 1987; 79:790-800.

49. Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, Neifing JL, Ward WK, Beard JC, Palmer JP, Porte D. Quantification of the relationship between insulin sensitivity and ß cell function in human subjects: evidence for a hyperbolic function. Diabetes 1993; 42:1663-1672.

50. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care 1997; 20:537-544.

51. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344:1343-1350. f

52. The Diabetes Prevention Program Research Group. The Diabetes Prevention Pro-

Diabetes 2

Diabetes 2

Diabetes is a disease that affects the way your body uses food. Normally, your body converts sugars, starches and other foods into a form of sugar called glucose. Your body uses glucose for fuel. The cells receive the glucose through the bloodstream. They then use insulin a hormone made by the pancreas to absorb the glucose, convert it into energy, and either use it or store it for later use. Learn more...

Get My Free Ebook

Post a comment